EUVIMEDSkopri EUVIMED
EUVIMED · CrossrefJournal

Kidney Cancer

ISSN 2468-4562 · SAGE Publications

Latest articles

  1. Real-World effectiveness of second-line cabozantinib in metastatic renal cell carcinoma in the era of immunotherapy combinations: Results from the international metastatic renal cell carcinoma database consortium (IMDC)

    Martin Zarba, Dylan E. O’Sullivan, Razane El Hajj Chehade, Rana R. McKay, Sumanta K. Pal, Benoit Beuselinck, Frede Donskov, Aly-Khan Lalani, Megan Crumbaker, Haoran Li, Ajjai S. Alva, Thomas Powles, Kosuke Takemura, Christian Kollmansberger, Shirley S. Wong, Lori A. Wood, Lisa Ludwig, Guillermo De Velasco, Winson Cheung, Toni K. Choueiri, Daniel Y.C. Heng

    Published: 2026-03-17DOI: 10.1177/24684562251411428

  2. Durable responses to immune checkpoint inhibitor-based regimens for metastatic clear cell renal cell carcinoma stratified by IMDC risk groups: A pooled analysis of four randomized phase 3 trials

    Albert Jang, Jeffrey Y. Zhong, Hamsa L.S. Kumar, Kevin K. Zarrabi, Alec Zhu, Abby L. Grier, Adam Calaway, Jonathan E. Shoag, Laura Bukavina, Angela Y. Jia, Prateek Mendiratta, Iris Y. Sheng, Santosh Rao, Jason R. Brown, Jorge A. Garcia, Seunghee Margevicius, Pingfu Fu, Pedro C. Barata

    Published: 2025DOI: 10.1177/24684570241311419

  3. Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)

    Steven M. Yip, Jose M. Ruiz Morales, Frede Donskov, Anna Fraccon, Umberto Basso, Brian I. Rini, Jae Lyun Lee, Georg A. Bjarnason, Hao-Wen Sim, Benoit Beuselinck, Ravindran Kanesvaran, James Brugarolas, Kostas Koutsoukos, Simon Yuen Fai Fu, Takeshi Yuasa, Ian Davis, Ajjai Alva, Christian Kollmannsberger, Toni K. Choueiri, Daniel Y.C. Heng

    Published: 2017DOI: 10.3233/kca-160002

Volumes

2026 · 22025 · 92024 · 232023 · 162022 · 272021 · 232020 · 272019 · 322018 · 192017 · 19

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.